SCHEMBL2878495

SCHEMBL2878495

N#Cc1cc2ncnc(Cl)c2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
AXL P30530 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
PSMB8 P28062 1/20 0.33
KDR P35968 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
RPS6KA5 O75582 1/20 0.31
RPS6KA4 O75676 1/20 0.31
MAP3K8 P41279 2/20 0.31
STK17B O94768 1/20 0.31
DYRK1A Q13627 1/20 0.31
SELE P16581 1/20 0.30
VCAM1 P19320 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2878910 0.82 NPC1 (0.43) NPC1RAB9AKMT2ATDP1AXL
SCHEMBL2873193 0.77 NPC1 (0.43) NPC1RAB9AKMT2ATDP1AXL
SCHEMBL2212567 0.74 PSMB8 (0.42) RAB9AKMT2APSMB8KDR
SCHEMBL2870197 0.72 NPC1 (0.46) NPC1RAB9AKMT2ATDP1AXL
SCHEMBL2798273 0.72 MAP3K8 (0.47) NPC1RAB9AKMT2ATDP1AXL
SCHEMBL4798991 0.72 KMT2A (0.50) NPC1RAB9AKMT2ATDP1AXL
SCHEMBL6827538 0.71 NPC1 (0.39) NPC1RAB9AKMT2ATDP1AXL
SCHEMBL6827094 0.71 NPC1 (0.39) NPC1RAB9AKMT2ATDP1AXL
SCHEMBL3980685 0.71 SELE (0.51) KMT2AKDRPDE4APDE4BPDE4C
SCHEMBL2876590 0.68 NPC1 (0.47) NPC1RAB9AKMT2ATDP1AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1768984-B1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS INC (US) 2010-10-20 EP disclosed
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
EP-1768984-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS Sunesis Pharmaceuticals, Inc. (US) 2007-04-04 EP disclosed
WO-2006036266-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2006-04-06 WO disclosed
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS AURKA, AURKB, AURKC NPC1 2384/4885RAB9A 2785/4885KMT2A 529/4885
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors AURKA, AURKB, AURKC NPC1 2374/4885RAB9A 2698/4885KMT2A 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.